Use of interleukin-22 in treating viral hepatitis
AssigneeGeneron (Shanghai) Corporation Ltd.
InventorsXiaoqiang Yan, Zhihua Huang, Hongzhou Yang, Yuliang Huang
Life of this patent
Estimating the term…
Abstract
This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by hepatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis.
Claims10
Use of a human IL-22 or a dimer thereof in the manufacture of a drug for treating viral hepatitis.
A human IL-22 dimer wherein said dimer is shown as of formula (I):
- M1-L-M2 (I)
- wherein
- M1 is a first human IL-22 monomer;
- M2 is a second human IL-22 monomer;
- and
- L is a linker connecting said first monomer and said second monomer and disposed therebetween;
- wherein said IL-22 dimer retains the biological activity of IL-22 and has a serum half-life of at least twice of the half-life of either said first or said second monomer.
A pharmaceutical composition for treating viral hepatitis comprising a pharmaceutically acceptable carrier and a human IL-22 dimer of formula (I):
- M1-L-M2 (I)
- wherein
- M1 is a first human IL-22 monomer;
- M2 is a second human IL-22 monomer;
- and
- L is a linker connecting said first monomer and said second monomer and disposed therebetween;
- wherein said IL-22 dimer retains the biological activity of IL-22 and has a serum half-life of at least twice of the half-life of either said first or said second monomer.
Dependencies are inferred from the claim text.